These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 32169258

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M, Sakai K, Hayashi H, Tanaka K, Haratani K, Takahama T, Kato R, Yonesaka K, Nishio K, Nakagawa K.
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
    Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC.
    Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY, Yu SF, Wang SH, Bai H, Zhao J, An TT, Duan JC, Wang J.
    Chin J Cancer; 2016 Mar 21; 35():30. PubMed ID: 27001083
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil.
    Palacio S, Pontes L, Prado E, Arshad J, Ali R, Piha T, Bacchi CE, Mudad R, Lopes G.
    Oncologist; 2019 Apr 21; 24(4):e137-e141. PubMed ID: 30446583
    [Abstract] [Full Text] [Related]

  • 14. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    Aye PS, Tin Tin S, McKeage MJ, Khwaounjoo P, Cavadino A, Elwood JM.
    BMC Cancer; 2020 Jul 14; 20(1):658. PubMed ID: 32664868
    [Abstract] [Full Text] [Related]

  • 15. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M, Mukhopadhyay M, Das C, Chatterjee S, Naskar BG.
    J Cancer Res Ther; 2021 Jul 14; 17(6):1389-1396. PubMed ID: 34916369
    [Abstract] [Full Text] [Related]

  • 16. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, Horinouchi H, Kanda S, Nokihara H, Watanabe S, Ichikawa H, Yamamoto N, Kuwano K, Ohe Y.
    Oncologist; 2016 Feb 14; 21(2):156-64. PubMed ID: 26768482
    [Abstract] [Full Text] [Related]

  • 17. Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.
    Xiao X, Sun Z, Liang S, Li W, Guo H, Zhao H, Zhao L, Ma H, Sun Y, Wang C, Chang X, Zhang Z.
    BMC Cancer; 2024 Jun 20; 24(1):749. PubMed ID: 38902688
    [Abstract] [Full Text] [Related]

  • 18. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J, French Cooperative Thoracic Intergroup (IFCT).
    Lung Cancer; 2020 Feb 20; 140():19-26. PubMed ID: 31841714
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.